On the basis of this pharmacokinetic difference, in the ongoing phase 3 clinical trial programme for IcoSema, an initial dose of IcoSema corresponding to 0.114 mg semaglutide has been selected, hence lower than the 0.25 mg recommended as starting dose for semaglutide alone [25,26,27]
Never stop taking any prescribed medication without consulting your doctor first
This isolation is dangerous, and it is one of the most underappreciated risks of grey-market purchasing
A 2023 analysis of gastrointestinal side effects on GLP-1 therapy noted that nausea and vomitingalready common in the first 4-8 weekswere exacerbated by alcohol in case reports and patient surveys
Licensed versus unlicensed prescribing Switching for non-formulary or intolerance reasons may constitute off-label use
But the effect is much smaller than prescription treatment